Clinical Research Directory
Browse clinical research sites, groups, and studies.
Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer
Sponsor: Hunan Cancer Hospital
Summary
This study is an open-label, multi-center Phase II clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate and platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer.
Official title: A Multi-Center Phase II Clinical Study of Camrelizumab Combined With Famitinib Malate and Platinum-based Chemotherapy in the Treatment of Recurrent/Metastatic Cervical Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
54
Start Date
2026-06-30
Completion Date
2029-03-30
Last Updated
2026-06-04
Healthy Volunteers
No
Conditions
Interventions
Camrelizumab
Intravenous (IV) on Day 1 of each cycle
Famitinib Malate
Famitinib po qd
Chemotherapy
Paclitaxel + cisplatin or carboplatin